SKIN CANCER DETECTION

Skin Pathologies

1. Actinic Keratosis and Intraepithelial Carcinoma / Bowen's Disease (AKIEC)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Precancerous lesion/squamous cell carcinoma *in situ*.	**RAG Output:** Stages of progression (AK Bowenoid invasive SCC).
Etiology/Risk Factors	Chronic **UV radiation** exposure (high factor), fair phototype (I-II), immunosuppression.	**Input:** Queries based on anamnesis (years of sun exposure, organ transplant).
Clinical Presentation (Morphology)	**Erythematous macule/papule** or flesh-colored, **rough to the touch** (**"sandpaper"** sensation), sometimes hyperkeratotic or atrophic. Borders often ill-defined.	**Input/Output:** Recognition of **focal hyperkeratosis/atrophy**, irregular, undefined borders.
Dermoscopy	**Rosette/yellow vessels**, **erythematous pseudonetwork**, follicular openings surrounded by a whitish halo. Bowenoid lesions: **glomerular structures**, gray-brown pigmentation.	**Input:** Vascular patterns (diagnostic specificity).
Histology (Gold Standard)	**Keratinocyte atypia** full-thickness (Bowen) or partial-thickness (AK), dermal **solar elastosis**, parakeratosis, dyskeratosis.	**RAG Output:** Identification of histological markers (e.g., mutant p53).
ICD-10 Code	L57.0 (AK), D04 (Carcinoma *in situ* of skin).	**Output:** Coding and billing.

---

2. Basal Cell Carcinoma (BCC)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Most common malignant skin neoplasm, slow-growing, derived from epidermal basal cells. Rarely metastasizes.	**RAG Output:** Low metastatic risk (distinguishing from MEL).
Main Subtypes	Nodular, Superficial, Morpheaform (Sclerosing), Pigmented.	**Input:** Histological classification.

Category	Key Technical Data	Relevance for AI (Input/Output)
Clinical Presentation (Morphology)	**Pearly/translucent nodule** with **arborizing telangiectasias** (typical), sometimes with central depression/ulceration (rodent ulcer). Superficial: erythematous and scaly plaque, confused with eczema. Pigmented: resembles melanoma.	**Input/Output:**Detection of **pearlescence**, **arborizing telangiectasias**.



| | **Dermoscopy** | **Arborizing vessels** (larger and more branched than AK), gray-blue **ovoid nests** (Nodular type), leaf-like areas, ulceration, white-red areas (Superficial type). | **Input:** Vascular patterns and non-melanocytic structures. | | **Histology (Gold Standard)** | **Nests of basal cells** with hyperchromatic nuclei and scant cytoplasm. Characteristic: **peripheral palisading** (cell alignment) and **retraction clefts** (artifact). | **RAG Output:** Correlation between palisading and diagnosis. | | **ICD-10 Code** | C44 (Malignant neoplasm of skin). | **Output:** Coding and follow-up. |

---

3. Benign Keratosis-like Lesions (BKL)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Group of benign, often hyperpigmented and elevated lesions that clinically mimic BCC or MEL. Includes Seborrheic Keratosis (SK), Seborrheic Verruca, Lichen Planus-like Keratosis (LPLK).	**RAG Output:** Critical differential diagnosis (vs. BCC, MEL).

Category	Key Technical Data	Relevance for AI (Input/Output)
SK (Morphology)	Light-to-dark brown, velvety/verrucous plaque/papule with a **"stuck-on"**appearance. **"Finger sign"** (lesion can be lifted).	**Input:** Recognition of the "stuck-on" quality.
Dermoscopy (SK)	**Milium-like cysts (pseudocysts)**, **comb-like (comedo-like)** follicular openings, hairpin vessels. Specific non-melanocytic structures.	**Input:** Absence of pigment network and arborizing vessels.
Histology (SK)	Proliferation of basal cells with keratinocytes and cystic formations (horny pseudocysts).	**RAG Output:**Exclusion of significant nuclear atypia.
LPLK	Benign inflammatory lesion that may show melanoma-like atypia histologically but has a band-like lymphocytic infiltrate.	**Input:** Inflammatory reaction as a diagnostic feature.
ICD-10 Code	L82 (Seborrheic keratosis).	**Output:** Treatment plan (observation/cosmetic removal).

---

4. Dermatofibroma (DF)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Slow-growing benign neoplasm composed of fibroblasts/histiocytes in the dermis. Hyperplastic reaction to trauma/insect bite (not always).	**RAG Output:**Reactive/traumatic nature.
Clinical Presentation (Morphology)	Firm, skin-colored/reddish-brown subcutaneous nodule. **Dimple sign (Fitzpatrick sign)**: the lesion retracts when compressed laterally.	**Input:** Recognition of the "dimple sign" (unique among lesions).
Dermoscopy	**Pigmented/fine peripheral rim** (**reticular pattern** often) with a **whitish/homogeneous central area** (scar-like). Specific structure.	**Input:** Central-peripheral pattern.
Histology (Gold Standard)	Proliferation of spindle cells (fibroblasts/histiocytes) in the dermis, often with **entrapped collagen** at the periphery.	**RAG Output:** Exclusion of atypia and abnormal mitoses.
ICD-10 Code	D23 (Other benign neoplasms of skin).	**Output:** Treatment (observation).

---

5. Melanoma (MEL)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Malignant neoplasm arising from melanocytes. High metastatic risk.	**RAG Output:** Risk stratification (Breslow, Clark).
Classifications	Superficial Spreading Melanoma (SSM), Nodular Melanoma (NM), Lentigo Maligna Melanoma (LMM), Acral Lentiginous Melanoma (ALM).	**Input:**Clinical/histological subtype.
Clinical Presentation (Morphology)	**ABCDE Rule**: **A**symmetry, **I**rregular **B**orders, **V**ariable **C**olor (3+ shades), **D**iameter mm, **E**volving/Elevation.	**Input:** Recognition of all ABCDE parameters.
Dermoscopy	Malignancy signs: **atypical network**, **pseudopods**, **blue-white veil**, **regression structures** (white scarring, pepper-like), **irregular dots/globules**, irregular punctate/linear vessels.	**Input:** Simultaneous detection of multiple malignancy patterns.



| | **Histology (Gold Standard)** | **Dermal invasion** by atypical melanocytes; large, irregular nuclei, prominent nucleoli, atypical mitoses. Prognostic indices: **Breslow thickness** (mm) and **Clark level** (anatomical). | **RAG Output:**Metastatic risk (T-stage). | | **ICD-10 Code** | C43 (Malignant melanoma of skin). | **Output:** Urgent triage and oncological follow-up. |

---

6. Melanocytic Nevi (NV)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Benign proliferation of melanocytes (nevus cells). Classified as Junctional, Compound, Intradermal	**RAG Output:** Low risk, transformation potential (negligible or moderate risk for atypical nevi).

Category	Key Technical Data (depending on location in dermis/epidermis).	Relevance for AI (Input/Output)
Clinical Presentation (Morphology)	Symmetrical, regular borders, homogeneous color (typically uniform brown), diameter mm, non-evolving.	**Input:** Dermoscopic **"beauty"**criteria (absence of ABCDE).
Dermoscopy	Benign structures: **regular pigment network**, **uniform globules** (at the periphery), homogeneous patterns (e.g., globular, reticular, exploded star, *cobblestone*).	**Input:** Recognition of benign structures and their symmetry.

MELANOCYTIC NEOPLASMS



| | **Histology** | Well-circumscribed nests of melanocytes, maturation in depth (cells become smaller and less pigmented as they descend into the dermis). Absence of significant nuclear atypia and mitoses. | **RAG Output:** Confirmation of benignity and absence of inverted

maturation. | | **Atypical Nevus (Dysplastic)** | Nevus with some ABCDE criteria. Dermoscopy: some signs of atypia, but overall organized structure. Requires surveillance. | **Input:** Balancing structural benignity with mild atypia. |

---

7. Vascular Lesions (VASC)

Category	Key Technical Data	Relevance for AI (Input/Output)
Definition	Proliferations of blood vessels (e.g., Angioma) or vascular malformations.	**RAG Output:** Distinction between proliferating lesions (hemangiomas) and non-proliferating lesions (malformations).
Common Types	Cherry Angioma, Spider Angioma, Pyogenic Granuloma (Lobular Capillary Hemangioma - PG).	**Input:** Specific subtype.
Angioma (Morphology)	Bright red papule/nodule (cherry), punctate (spider), often partially blanches with pressure (diapedesis).	**Input:** Red/blue-red color and compressibility.
Dermoscopy	**Homogeneous red-blue structures**, red-blue **lacunae**(circles). Pyogenic Granuloma: **scaly collarette**(white/yellow) and hemorrhagic ulcers (pseudolacunae).	**Input:** Detection of lacunae and organized vascular structures.
Histology (PG)	Lobular proliferation of small vessels (capillaries), separated by edema.	**RAG Output:** High risk of bleeding (for PG).
Differential Diagnosis	MEL (PG and nodular, pigmented), BCC.	**Input:** Exclusion of melanocytic structures.
ICD-10 Code	D18.0 (Hemangioma).	**Output:** Treatment plan (laser, excision for PG).

Actinic Keratoses and Intraepithelial Carcinoma / Bowen's Disease (akiec)

Actinic keratosis (AK) is a common precancerous lesion caused by chronic ultraviolet (UV) exposure, representing an intraepidermal proliferation of atypical keratinocytes. It is considered an early in situ squamous cell carcinoma (SCC) with potential progression to invasive SCC in 5–10% of cases (higher in immunosuppressed patients, up to 30%). Clinically, AK presents as rough, scaly patches on sun-exposed skin (face, scalp, ears, forearms, dorsum of hands), often erythematous or hyperkeratotic, with variants including hypertrophic, atrophic, pigmented, and bowenoid types.

Bowen's disease (BD), or SCC in situ, involves full-thickness epidermal atypia without dermal invasion. It appears as well-demarcated, scaly, erythematous plaques, often on sun-exposed or non-exposed sites (e.g., lower legs in women). Bowenoid AK is a histologic

overlap with bowenoid features in AK. Key differences: AK atypia is partial-thickness (basal layers), while BD is full-thickness; preserved basal cytokeratin expression in BD vs. sporadic in AK.

Clinical Features:

- AK: Multiple lesions, "strawberry" dermoscopy (red pseudonetwork, white-yellow scale, rosettes).
- BD: Solitary plaque, glomerular vessels on dermoscopy, clustered dots/lines in pigmented variants.

Histopathology:

- AK: Atypical keratinocytes in lower epidermis, parakeratosis, solar elastosis; graded I–III (increasing atypia/progression risk).
- BD: Full-thickness atypia, disordered maturation, mitoses throughout epidermis; may show clonal or pagetoid patterns.

Risk Factors and Progression: UV damage, fair skin, immunosuppression; HPV implicated in some genital BD. Progression: AK → invasive SCC (0.1–16% lifetime); BD → invasive SCC (3–5%).

Diagnosis: Clinical + dermoscopy; biopsy for confirmation (essential if invasive suspected). Differential: SCC, BD, seborrheic keratosis, lentigo maligna.

Management (per guidelines, e.g., European S3/AAD):

- Field-directed: Cryotherapy, 5-FU, imiquimod, ingenol mebutate, photodynamic therapy (PDT), diclofenac gel.
- Lesion-directed: Curettage, excision for hypertrophic/bowenoid.
- Follow-up: High-risk patients every 6–12 months.

Basal Cell Carcinoma (bcc)

BCC is the most common skin cancer (>80% of non-melanoma skin cancers), arising from basal keratinocytes, driven by Hedgehog pathway mutations (PTCH1). Slow-growing, locally invasive, rarely metastasizes (<0.1%).

Clinical Features: Nodular (pearly nodule with telangiectasia, rolled borders), superficial (scaly patch), morpheaform/sclerosing (indurated plaque), pigmented variants. Sites: Sun-exposed (head/neck 70%).

Dermoscopy: Arborizing vessels, blue-gray ovoid nests, leaf-like areas, ulceration.

Histopathology: Basaloid islands with peripheral palisading, stromal retraction, mucin; subtypes: nodular, superficial, infiltrative (higher recurrence).

Risk Factors: UV exposure, fair skin, Gorlin syndrome (multiple early BCCs).

Diagnosis: Biopsy (shave/punch); staging per AJCC 8th edition.

Management (per AAD/NCCN/EADO guidelines):

- Low-risk: Curettage/ED&C, topical (imiquimod/5-FU for superficial), cryotherapy, PDT.
- High-risk/aggressive: Mohs surgery (preferred for face/high-recurrence areas), standard excision (4–6 mm margins), radiation (elderly/non-surgical).
- Advanced/metastatic: Hedgehog inhibitors (vismodegib/sonidegib), PD-1 inhibitors (cemiplimab).
- Follow-up: Lifelong skin exams (new BCC risk 30–50% in 5 years).

Benign Keratosis-Like Lesions (bkl)

This category encompasses seborrheic keratosis (SK), solar lentigo (SL), and lichen planus-like keratosis (LPLK/benign lichenoid keratosis).

Seborrheic Keratosis: Most common benign epithelial tumor, "stuck-on" warty plaques, tan-brown-black, often multiple in elderly. Dermoscopy: Milia-like cysts, comedo-like openings, fissures/ridges, moth-eaten borders.

Solar Lentigo: Flat, pigmented macules on sun-exposed skin; dermoscopy: Moth-eaten borders, fingerprint/jelly sign.

Lichen Planus-Like Keratosis: Inflammatory regression of SL/SK; solitary red-brown plaque with gray granules on dermoscopy (regression).

Histopathology: SK: Acanthosis, papillomatosis, horn cysts; SL: Lentiginous hyperplasia; LPLK: Lichenoid infiltrate with interface changes.

Diagnosis: Clinical/dermoscopic; biopsy if atypical (rule out melanoma/lentigo maligna).

Management: None required (benign); cryotherapy, curettage, shave excision for cosmetic/itch.

Dermatofibroma (df)

Benign fibrohistiocytic proliferation, often post-trauma/insect bite. Firm, reddish-brown nodule (legs > arms), dimple sign on lateral compression.

Clinical Features: 0.5–1 cm, hyperpigmented halo common; variants: Aneurysmal (hemorrhagic), cellular (higher recurrence).

Dermoscopy: Central white patch, delicate pigment network periphery.

Histopathology: Dermal spindle cells in storiform pattern, collagen trapping at edges, factor XIIIa+, CD34-.

Diagnosis: Clinical + dermoscopy; biopsy if atypical.

Management: Observation; excision if symptomatic/recurrent (rare local recurrence).

Melanoma (mel)

Malignant melanocyte proliferation; most lethal skin cancer. Subtypes: Superficial spreading (70%), nodular, lentigo maligna, acral lentiginous.

Clinical Features: ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter >6 mm, Evolution); dermoscopy: Atypical network, streaks, dots/globules, blue-white veil.

Histopathology: Atypical melanocytes, pagetoid spread, asymmetry; Breslow thickness key prognosticator.

Risk Factors: UV, fair skin, nevi count, family history, CDKN2A mutations.

Diagnosis: Excisional biopsy with margins; sentinel node biopsy if >0.8 mm or ulcerated.

Management (per NCCN/ESMO/AAD):

- Stage 0/I–II: Wide excision (margins 1–2 cm based on Breslow).
- Stage III: Node dissection/SLNB + adjuvant immunotherapy (PD-1) or targeted (BRAF/MEK if mutated).
- Stage IV: Immunotherapy (nivolumab/ipilimumab), targeted therapy (dabrafenib/trametinib), clinical trials.
- Follow-up: Stage-dependent imaging/surveillance.

Melanocytic Nevi (nv)

Benign melanocyte proliferations; acquired (most) or congenital.

Classification:

- Junctional: Flat, nested at dermoepidermal junction.
- Compound: Raised, junctional + dermal.
- Intradermal: Dome-shaped, dermal only.
- Special: Blue (dermal melanocytes), Spitz (children, epithelioid cells), dysplastic/atypical (architectural disorder, random atypia).

Clinical Features: Uniform color/size, symmetric; evolve over life (junctional → compound → dermal).

Dermoscopy: Globular, reticular, homogeneous patterns.

Histopathology: Nested, symmetric, maturation with depth.

Diagnosis: Clinical monitoring; excision if changing/atypical.

Management: Observation; excision for atypia/cosmesis; high-risk patients (many nevi/familial) regular screening.

Vascular Lesions (vasc)

Includes infantile hemangioma (not in HAM10000 adults), cherry angioma, pyogenic granuloma (lobular capillary hemangioma), venous lake.

Pyogenic Granuloma: Rapidly growing red papule/nodule, friable/bleeds; post-trauma/pregnancy.

Cherry Angioma: Bright red papules, trunk.

Dermoscopy: Red lacunae, white rail lines (PG).

Histopathology: Lobular capillaries, collarette (PG); GLUT1- (vs. infantile hemangioma +).

Diagnosis: Clinical; biopsy if uncertain.

Management: Observation (cherry); shave/excision, laser, sclerotherapy for symptomatic PG.

Comprehensive Skin Cancer Prevention Strategies

Skin cancer (BCC, SCC, melanoma) is the most preventable cancer. Effective prevention focuses on reducing ultraviolet radiation (UVR) exposure—the primary modifiable risk factor—combined with early detection and risk-based surveillance.

1. Primary Prevention: UV Protection (Most Important)

Strategy	Details & Evidence Level	Practical Tips
Sun avoidance	Avoid outdoor activities 10 AM–4 PM when UV index ≥3	Use UV index apps (e.g., EPA SunWise)
Seek shade	Especially during peak hours; shade reduces UV by ~50%	Umbrellas, trees, awnings
Protective clothing	Long sleeves, pants, broad-brimmed hats, sunglasses	UPF 40–50+ clothing (one layer = SPF ~7–10)
Broad-spectrum sunscreen	SPF ≥30 (blocks ~97% UVB), water-resistant, reapply every 2 h & after swimming/sweating	Use ~1 oz (shot glass) per application; lip balm with SPF
Avoid tanning beds	WHO Class 1 carcinogen; one session <35 yo ↑ melanoma risk 59–75%	Complete avoidance recommended by AAD, WHO, CDC

2. Chemoprevention (For Very High-Risk Individuals Only)

Agent	Indication	Evidence
Oral nicotinamide (500 mg BID)	Organ-transplant recipients, multiple AKs/SCCs/history of NMSC	Reduces new AKs ~20%, NMSC ~23% (ONTRAC trial)

Agent	Indication	Evidence
Acitretin / isotretinoin	High-risk (Gorlin syndrome, XP, multiple prior SCCs)	Reduces new SCCs/BCCs; significant side effects
Topical 5-FU (field therapy)	Extensive actinic damage	Prevents SCC in high-risk fields

3. Risk Stratification & Secondary Prevention (Early Detection)

Risk Group	Examples	Recommended Screening
General population	Average risk	Annual full skin exam starting ~age 20–40 (controversial) + self-exam
Moderate risk	>50 common nevi, fair skin, occasional severe sunburn history	Dermatologist every 1–2 years
High risk	Personal/family history of melanoma, dysplastic nevus syndrome, multiple prior NMSC, immunosuppression	Every 3–12 months + total-body photography & dermoscopy
Very high risk	Organ transplant, xeroderma pigmentosum, Gorlin syndrome	Every 3–6 months

4. Self-Examination & Public Education

- Monthly skin self-exam using ABCDE rule for melanoma and “ugly duckling” sign
- Teach patients to check scalp, back, soles, nails, genitals
- Apps (e.g., UMSkinCheck, SkinVision) can assist but do not replace professional exam

5. Special Populations

Group	Additional Recommendations
Children & adolescents	Strict sun protection; no tanning beds <18 yo (legal in many places)
Outdoor workers	Mandatory sun-safe policies, protective clothing, scheduled shade breaks
Immunosuppressed (transplant, HIV, CLL)	Aggressive field therapy of AKs, frequent screening, consider prophylactic acitretin/nicotinamide
Genetic syndromes (XP, Gorlin, FAMMM)	Lifelong rigorous protection, often indoor lifestyle

6. Current Guideline Recommendations (2024–2025)

- AAD: Regular sunscreen use, protective clothing, avoid tanning beds; screening based on risk
- USPSTF (2023, still current): Insufficient evidence to recommend routine total-body skin exam in asymptomatic average-risk adults, but supports counseling on UV minimization
- NCCN: Risk-stratified screening intervals
- WHO/IARC: Treat solar UVR as proven carcinogen → population-level interventions (shade structures in schools, vitamin D guidance without excess sun)

Key Take-Home: Combining behavioral UV protection (clothing + shade + sunscreen) is far more effective and cost-efficient than relying on sunscreen alone. For an average fair-skinned person, lifelong adherence to strict sun protection can reduce melanoma risk by ~50–80% and NMSC even more dramatically.

Vitamin D Balance in Skin Cancer Prevention

Achieving adequate vitamin D status is important for bone health, immune function, and possibly reduced risk of some internal cancers, but excessive intentional UV exposure to "get vitamin D" is **not recommended** by any major dermatology or cancer organization. Safe, evidence-based strategies allow excellent vitamin D levels with minimal or zero additional skin cancer risk.

Key Evidence (as of November 2025)

Statement	Evidence Level	Source
Sun exposure is a highly inefficient and risky way to produce vitamin D	High	Holick et al., AAD, Cancer Council Australia
Skin cancer risk increases linearly with cumulative UV exposure; no safe threshold for intentional tanning	High	IARC/WHO, Green et al. (Lancet 2011 & updates)
Most people can maintain sufficient 25(OH)D (>20–30 ng/mL or >50–75 nmol/L) without any deliberate sun exposure	High	Vieth, SACN UK, Endocrine Society
Intentional UV exposure for vitamin D provides no proven net health benefit over supplements/diet	Moderate–High	AAD 2023 position statement, USPSTF

Recommended Safe Vitamin D Strategies (Zero Additional Skin Cancer Risk)

Population	Serum 25(OH)D Target	Primary Source	Daily Amount	Notes
General adults (<70 y)	≥20 ng/mL (50 nmol/L) – sufficient for 97.5% of population	Diet + supplements	600–800 IU (15–20 µg)	IOM/NAM recommendation
Adults ≥70 y, or limited synthesis (dark skin, obesity, malabsorption)	≥30 ng/mL (75 nmol/L) preferred by many experts	Supplements	1,000–4,000 IU	Safe upper limit 4,000 IU/day (IOM); Endocrine Society allows up to 10,000 IU
High-risk skin cancer patients (history of melanoma/NMSC, organ transplant, xeroderma pigmentosum)	30–50 ng/mL	Supplements only (avoid sun)	1,000–2,000 IU typical	Monitor levels annually; nicotinamide still compatible

Population	Serum 25(OH)D Target	Primary Source	Daily Amount	Notes
Children 1–18 y	≥20 ng/mL	Food + supplements if needed	600–1,000 IU	AAP

Best food sources (per serving):

- Salmon (wild, 3.5 oz): ~600–1,000 IU
- Fortified milk/orange juice (1 cup): ~100–120 IU
- Egg yolk: ~40 IU
- UV-exposed mushrooms: variable, up to 400 IU/100 g

Practical Clinical Advice for Dermatologists / Patients

1. **Never recommend unprotected sun exposure** for vitamin D — even 5–15 minutes of midday summer sun on arms/face can deliver 5,000–10,000 IU but also significant DNA damage.
2. Measure 25(OH)D in high-risk patients (transplant, multiple skin cancers, elderly, dark-skinned individuals living at high latitude in winter).
3. Supplement year-round if levels <30 ng/mL, especially October–April above 35° latitude.
4. Re-check levels after 3 months of supplementation; aim for 30–50 ng/mL (avoid >100 ng/mL — no benefit, rare toxicity risk).
5. Combine with strict photoprotection — sunscreen (SPF ≥30) reduces vitamin D synthesis by >95%, but real-world studies show regular sunscreen users still maintain normal levels via dietary sources and incidental exposure.

Current Consensus Statements (2024–2025)

- American Academy of Dermatology (2023, reaffirmed 2025): "Physicians should counsel patients that vitamin D can be obtained safely through diet and supplements without increasing skin cancer risk."
- International Consensus (Lancet Diabetes Endocrinol 2024): No justification for intentional UV exposure; supplementation is safe and effective.
- Cancer Council Australia (2024 update): "When the UV index is ≥3, sun protection is required. Vitamin D should be obtained from diet/supplements."

Bottom line: Optimal vitamin D status and rigorous skin cancer prevention are completely compatible — and achieved most safely with supplements and fortified foods, not sun exposure.

Vitamin D Deficiency: Symptoms Overview

Vitamin D deficiency (typically defined as serum 25-hydroxyvitamin D [25(OH)D] <20 ng/mL or <50 nmol/L) is common worldwide, but **many people are asymptomatic**,

especially in mild or moderate cases. Symptoms, when present, are often subtle and nonspecific, developing gradually due to impaired calcium/phosphorus absorption, secondary hyperparathyroidism, and effects on muscle/bone function. Severe, prolonged deficiency leads to more overt skeletal manifestations.

Common Symptoms in Adults

Symptom Category	Specific Symptoms	Notes / Prevalence
Musculoskeletal	Bone pain (often lower back, pelvis, thighs), muscle weakness (especially proximal, e.g., difficulty rising from chair or climbing stairs), muscle aches/myalgias, muscle cramps/twitching (fasciculations), throbbing bone pain on pressure (sternum/tibia)	Most characteristic; often misdiagnosed as fibromyalgia, chronic fatigue, or age-related issues.
General/Fatigue	Persistent fatigue/tiredness, general aches and pains	Very common but nonspecific.
Mental Health	Depression, low mood, anxiety	Observational associations; supplementation may improve in deficient individuals.
Immune-Related	Frequent infections/illness, slower wound healing	Due to vitamin D's role in immune modulation.
Other	Hair loss (alopecia, controversial), increased falls/fractures risk (especially elderly)	Fractures often from minor trauma; osteoporosis/osteomalacia in chronic cases.

Severe Deficiency Manifestations

- **Osteomalacia** (softening of bones in adults): Diffuse bone pain, fragility fractures, waddling gait, deformities (e.g., kyphosis).
- Symptoms from hypocalcemia (rare in adults unless very severe): Tetany, seizures, arrhythmias.

Symptoms in Children and Infants

Condition	Key Symptoms
Rickets (severe deficiency)	Bowed legs, knock-knees, delayed growth, skeletal deformities (e.g., rachitic rosary = rib beading, wrist widening), muscle weakness, bone pain, increased fracture risk, dental problems.
Mild/Moderate	Weak/sore/painful muscles, irritability, developmental delays.

Important Clinical Notes (as of 2025)

- **Many cases are asymptomatic** — Diagnosis often incidental via blood test in at-risk groups (e.g., limited sun exposure, dark skin, obesity, malabsorption, elderly, strict photoprotection for skin cancer prevention).

- Symptoms overlap with many conditions (e.g., hypothyroidism, fibromyalgia, depression) — Always confirm with 25(OH)D level; do not diagnose based on symptoms alone.
- No symptom is pathognomonic; evidence for causation (vs. association) is stronger for musculoskeletal effects than mood/immune symptoms.
- In high-risk skin cancer patients adhering to strict sun avoidance, routine monitoring and supplementation prevent deficiency without UV risk.

If symptoms are present, consult a healthcare provider for testing (25(OH)D level) and safe repletion — Do not self-diagnose or mega-dose without guidance, as excess can cause toxicity.

Causes of Vitamin D Deficiency

Vitamin D deficiency (25(OH)D <20 ng/mL or <50 nmol/L) is extremely common worldwide (affecting ~40–100% of populations depending on latitude, season, and demographics). It results from inadequate production in the skin, reduced absorption, or increased catabolism/loss.

Category	Specific Causes	Mechanism / Explanation	High-Risk Groups
Reduced cutaneous synthesis (most common cause globally)	Limited sun exposure	Strict photoprotection (sunscreen SPF ≥30 blocks >95% synthesis), indoor lifestyle, high latitude (>35–40°), winter months, air pollution, clothing coverage	Dermatologists' patients with skin cancer history, office workers, elderly in nursing homes, veiled women, night-shift workers
	Aging	↓7-dehydrocholesterol in skin → ~75% reduced synthesis capacity at age 70 vs. 20	Elderly (>70 y)
	Darker skin tones (Fitzpatrick IV–VI)	Melanin absorbs UVB → 5–10× longer sun exposure needed for same synthesis	African, South Asian, Hispanic populations at high latitudes
	Obesity (BMI ≥30)	Sequestration of fat-soluble vitamin D in adipose tissue → lower circulating 25(OH)D	Obese individuals (often need 2–3× higher doses)
Inadequate dietary intake	Low natural food sources + no supplementation	Very few foods naturally rich (fatty fish, egg yolks); fortification varies by country	Vegans, lactose-intolerant, elderly with poor appetite

Category	Specific Causes	Mechanism / Explanation	High-Risk Groups
Malabsorption	Celiac disease, Crohn's, ulcerative colitis, gastric bypass, pancreatic insufficiency, cystic fibrosis	Reduced fat absorption → ↓ vitamin D absorption (fat-soluble)	Bariatric surgery patients, IBD, chronic cholestasis
Medications	Anticonvulsants (phenytoin, phenobarbital, carbamazepine), rifampin, glucocorticoids, antiretrovirals (efavirenz), ketoconazole	Induce CYP3A4 → ↑ catabolism of 25(OH)D and $1,25(OH)_2D$	Epilepsy, TB, HIV patients on long-term therapy
Liver disease	Chronic liver failure, cirrhosis	Impaired 25-hydroxylation of vitamin D	Advanced liver disease
Kidney disease	CKD stages 3–5 (eGFR <60)	Impaired 1α-hydroxylation → low $1,25(OH)_2D$ (active form); also ↑FGF-23 → ↓$1,25(OH)_2D$	Chronic kidney disease, dialysis patients
Genetic / rare disorders	Hereditary vitamin D-resistant rickets, pseudovitamin D deficiency rickets	Mutations in vitamin D receptor or 1α-hydroxylase	Rare, usually pediatric
Increased demand / loss	Pregnancy & lactation, rapid growth (infants/children)	Higher requirements; nephrotic syndrome → urinary loss of vitamin D-binding protein	Pregnant/breastfeeding women, premature infants

Practical Clinical Ranking (Most to Least Common in Dermatology/Skin Cancer Prevention Patients)

1. Strict sun avoidance + sunscreen/clothing use (very common in melanoma/NMSC survivors)
2. Aging + indoor lifestyle
3. Obesity
4. Dark skin at northern latitudes
5. Malabsorption (e.g., post-bariatric surgery increasing)
6. Medications (especially anticonvulsants, glucocorticoids)

Key takeaway for skin cancer prevention patients: Rigorous photoprotection is the leading cause of deficiency in this population. Routine screening (annual 25(OH)D level) and prophylactic supplementation (typically 1000–2000 IU/day) are strongly recommended without compromising UV protection.

Vitamin D Supplementation Guidelines (2025 Update)

Major organizations slightly differ in definitions and targets, but all agree: supplementation is safe, effective, and preferred over intentional UV exposure.

Organization / Year	Population	Definition of Deficiency	Sufficiency Target	Recommended Daily Intake (Maintenance)	High-Risk / Treatment Dosing	Key Notes
Institute of Medicine (IOM/NAM) 2011 (still widely used)	General population	<12 ng/mL (<30 nmol/L) risk of deficiency	≥20 ng/mL (50 nmol/L) sufficient for 97.5%	600 IU (0–70 y) 800 IU (>70 y)	Up to 4,000 IU/day safe upper limit	Bone health focus; conservative
Endocrine Society 2024 update	Adults at risk (obesity, dark skin, malabsorption, strict photoprotection)	<20 ng/mL deficient	≥30 ng/mL (75 nmol/L) preferred (especially >65 y or high-risk)	1,500–2,000 IU/day	Obesity/malabsorption: 3,000–6,000 IU/day Treatment: 50,000 IU/week × 8–12 wk or 6,000 IU/day × 8–12 wk, then maintenance	Most relevant for dermatology/skin cancer patients
American Academy of Dermatology (AAD) 2023/2025 position	Patients practicing rigorous photoprotection (melanoma/NMSC survivors, organ transplant)	—	30–50 ng/mL	1,000–2,000 IU/day (D_3)	Same as Endocrine Society	Explicitly states supplements preferred over sun exposure
SACN (UK) 2016/2024 reaffirm	General UK population (low winter synthesis)	<10 ng/mL (<25 nmol/L)	Year-round ≥10 ng/mL	400 IU (10 µg) all ages	Higher doses for deficiency	Recommends year-round supplementation Oct–Mar

Organization / Year	Population	Definition of Deficiency	Sufficiency Target	Recommended Daily Intake (Maintenance)	High-Risk / Treatment Dosing	Key Notes
Global Consensus (Lancet Diabetes Endocrinol) 2024	High-risk skin cancer prevention	—	≥30 ng/mL	1,000–4,000 IU/day	Treatment same as Endocrine	"No justification for UV exposure to obtain vitamin D"
NICE (UK) 2024	High-risk groups (including strict sun avoiders)	—	—	800–2,000 IU/day (or higher if deficient)	300,000 IU stat dose possible in severe cases under supervision	

Preferred Form

- **Vitamin D_3 (cholecalciferol)** > D_2 (ergocalciferol) — better at raising and sustaining 25(OH)D levels.
- Daily or weekly dosing equally effective; monthly high-dose may be slightly less effective long-term.

Practical Dosing Algorithm for Dermatology/Skin Cancer Patients (2025)

Scenario	Initial Dose	Duration	Maintenance	Monitoring
Strict photoprotection, no known deficiency	1,000–2,000 IU D_3 daily	Ongoing	Same	Check 25(OH)D annually
Known deficiency (<20 ng/mL)	5,000–6,000 IU daily OR 50,000 IU weekly	8–12 weeks	1,000–2,000 IU daily	Recheck after 3 months
Obesity (BMI ≥30) or malabsorption	Double or triple usual dose (often 3,000–6,000 IU/day)	—	Same	Levels often remain low without higher doses
Organ transplant / very high-risk NMSC	2,000–4,000 IU daily (often combined with nicotinamide)	Ongoing	Same	Annual or 6-monthly levels

Safety & Toxicity

- Upper safe limit: 4,000 IU/day (IOM) to 10,000 IU/day (Endocrine Society) for adults.
- Toxicity (>150 ng/mL) extremely rare below 10,000 IU/day long-term; symptoms: hypercalcemia, kidney stones, confusion.
- No increased skin cancer risk from supplementation (multiple large cohort studies/RCTs).

Key Take-Home for Dermatologists (2025)

- Routinely recommend 1,000–2,000 IU vitamin D_3 daily to all patients practicing rigorous sun protection.
- Check baseline 25(OH)D in melanoma/NMSC survivors, transplant recipients, elderly, obese, dark-skinned individuals at high latitude.
- Target 30–50 ng/mL — easily achievable with safe oral supplementation and zero additional UV risk.

Supplementation fully reconciles optimal vitamin D status with maximal skin cancer prevention.

. Actinic keratoses & intraepithelial carcinoma / Bowen's disease (akiec)

- **Intraepidermal SCC / Bowen's disease overview** – DermNet NZ: pathogenesis, clinical variants, histology, treatment. DermNet®
- **Actinic keratoses & Bowen's disease guideline (NHS Lothian)** – practical diagnostic tips, risk of progression, treatment algorithms. apps.nhslothian.scot
- **Actinic keratosis vs Bowen disease as intraepidermal squamous neoplasia** – clinicopathologic review clarifying continuum and differences. ScienceDirect

---

2. Basal cell carcinoma (bcc)

- **British Association of Dermatologists BCC guideline (2021)** – gold-standard evidence-based management (risk stratification, surgery, topicals, radiotherapy, systemic). OUP Academic+1
- **PCDS BCC overview** – clinical subtypes, dermoscopy, referral criteria for primary/secondary care. Primary Care Dermatology Society+1

---

3. Benign keratosis-like lesions (bkl)

(seborrhoeic keratoses, solar lentigines, lichenoid keratoses / LPLK)

- **Seborrhoeic keratosis – PCDS guideline** – epidemiology, clinical patterns, red flags. Primary Care Dermatology Society
- **Dermoscopy of seborrhoeic keratosis – DermNet NZ + Dermoscopedia** – classic structures (milia-like cysts, comedo-like openings, fissures/ridges, moth-eaten borders). DermNet®+2Dermoscopedia.org+2
- **Lichenoid / lichen planus-like keratosis – DermNet + PCDS + Dermoscopedia** – clinical behaviour, histology, dermoscopic patterns and pitfalls vs lentigo/melanoma. ijpgderma.org+4DermNet®+4Primary Care Dermatology Society+4

---

4. Dermatofibroma (df)

- **Dermoscopedia "Dermatofibroma" chapter** – central white patch, peripheral pigment network, ring-like globules, shiny white lines. Dermoscopedia.org
- **JAAD "dermoscopic variability of dermatofibromas"** – variants (aneurysmal, atrophic, pigmented) and their dermoscopic patterns. JAAD

---

5. Melanoma (mel)

- **ESMO / European melanoma guidelines (2023–2024)** – staging, work-up, surgical margins, systemic therapy. Annals of Oncology+2ScienceDirect+2
- **EADO 2024 melanoma diagnostics & treatment guidelines** – dermoscopy, imaging, follow-up protocols. eado.org
- **NICE NG14 Melanoma guideline** – UK-style assessment and management, good for structured pathways. NICE

---

6. Melanocytic nevi (nv)

- **PCDS "Benign melanocytic naevi" chapter** – clinical subtypes, risk factors, follow-up. Primary Care Dermatology Society
- **DermNet dermoscopy course: benign melanocytic lesions** – global patterns, networks, dots/globules, special sites. DermNet®
- **Clinical–dermoscopic–histopath correlation of common nevi** – detailed feature mapping, useful for AI feature engineering. JCAD

---

7. Vascular lesions (vasc)

- **DermNet dermoscopy of other non-melanocytic / vascular lesions** – hemangioma, pyogenic granuloma, lymphatic lesions, Kaposi sarcoma. DermNet®+2DermNet®+2
- **MSD Manual "Vascular lesions of the skin"** – taxonomy (tumors vs malformations), key entities. MSD Manuals
- **Frontiers in Medicine dermoscopic features of vascular anomalies** – comparative dermoscopy of IH, cherry angioma, angiokeratoma, PG. Frontiers
- **Reviews on cutaneous vascular tumors/anomalies** – clinical, histologic and management overviews.

Other info can be found here:
https://books.google.it/books?id=cf8CEQAAQBAJ&printsec=frontcover&hl=it#v=onepage&q&f=false